Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Makes progress toward reaching net zero status for direct and indirect emissions.
May 6, 2025
By: Charlie Sternberg
Vetter, a global contract development and manufacturing organization (CDMO), has published its fourth annual sustainability report, which shows how the business is actively pursuing ambitious sustainability goals in climate protection, social responsibility, and business operations.
“Our fourth sustainability report shows that successful sustainability progress is a marathon, not a sprint,” explains Managing Director Henryk Badack. “As a family-owned business, we have been taking responsibility for many decades – and not just for the environment. Our employees and the social environment are also particularly important to us. Our commitment to sustainability in these areas is as strong as our dedication to climate and energy. While we take pride in our successes to date, we cannot rest on our laurels. We will continue to consistently pursue our sustainability strategy to achieve the ambitious goals we’ve set.”
Vetter committed to reach net zero status for direct and indirect emissions in Germany by 2040, and worldwide by 2050. In other words, the CDMO needs to reduce its CO2 emissions by at least 4.52% each year, which it surpassed in 2024. To this end, the company is investing in infrastructure and process optimizations to assist in reaching these goals.
In addition to a new high-performance photovoltaic (PV) system at its Langenargen production site and the electrification of existing systems, Vetter is taking an important step towards hydrogen technology by converting two high-pressure steam generators. With an output of 128 kWp per year, the newest photovoltaic system generates as much energy as 29 family homes consume on average. In addition, the company uses solely CO₂-neutral nitrogen as of 2024 to further improve its carbon footprint. Together with all existing energy measures, 54% of Vetter’s energy consumption comes from renewable energy. The CDMO further emphasizes the sustainability of its partners, vendors, and suppliers by prioritizing their adherence to sustainable practices.
Its new training center for scientific professions underscores Vetter’s commitment to nurturing young talents in-house. By providing comprehensive training and appropriate infrastructure, the company aims to retain these individuals and employ them as skilled professionals to support international biopharma customers.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !